CSL Behring names new COO

Paul McKenzie, who joined Biogen in 2016 as executive vice president of pharmaceutical operations and technology, has been named Chief Operating Officer at CSL Behring in King of Prussia, PA. CSL Behring, a leading global biotech company, saw its share price rise 30% in 2018, helped in part by Haegarda for treating hereditary angioedema, and Idelvion, a factor IX hemophilia B treatment.

Paul will develop strategy and oversee the global supply chain.

Click here to view the entire article.